Previous view was $76M-$835M. Sees FY adjusted net income $70M-$85M vs. prior view of $45M-$70M. Sees FY adjusted EBITDA view $195M-$210M vs. prior view of $175M-$200M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions reports Q3 EPS $1.06 vs. $1.37 last year
- EBS Upcoming Earnings Report: What to Expect?
- Officials confirm community spread of new Mpox strain in Southern CA, NBC says
- Officials confirm case of severe mpox strain with no travel history, ABC says
- Emergent BioSolutions: Strong Market Position and Growth Potential with a Buy Rating